No abstract available
Keywords:
complement inhibitors; myasthenia gravis; neonatal Fc receptor antagonist; new treatments; rituximab; thymectomy; treatment strategy.
Grants and funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.